IBRX:NASDAQImmunityBio, Inc. Analysis
Data as of 2026-08-16 - not real-time
$7.57
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $7.57, ImmunityBio, Inc. shows no decisive moving-average alignment, leaving the trend neutral. Across the trailing 30 sessions it lost 19.8%. With RSI at 50.5 the momentum picture is neutral, alongside a bullish MACD signal. Price has been bracketed by support at $6.65 and resistance at $8.14.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 68.4% above the current quote. Revenue is growing at 93.9%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 60.5%, a beta of 1.58 and a maximum drawdown of 42.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 3/10 conviction over the longer horizon.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 68.4% above the current quote. Revenue is growing at 93.9%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 60.5%, a beta of 1.58 and a maximum drawdown of 42.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 3/10 conviction over the longer horizon.
Top Market Events
Aug 4, 2026 0 SAN DIEGO AP — SAN DIEGO AP — ImmunityBio, Inc.David Moadel Jul 10, 2026 0 Quick Read - MRNA dropped 11% and IBRX fell 8% on pure profit-taking after surging 160% and...Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Trading above the 200-day average of 6.16
- MACD momentum is positive
- 30-day price change of -19.8%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 6.16
- Analyst targets imply +68.4% versus the current price
- 30-day volatility of 60.5%
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Analyst targets imply +68.4% versus the current price
- Revenue growth of +93.9%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth93.90%
P/E Ratio-59.8
ROA-30.54%
P/B Ratio-7.6
Op. Cash Flow$-281137984
Free Cash Flow$-186564128
Industry P/E29.8
Technical Analysis
TrendNeutral
RSI50.5
Support$6.65
Resistance$8.14
MA 20$7.37
MA 50$7.65
MA 200$6.16
MACDBullish
VolumeStable
Fear & Greed Index95.98
Valuation
Target Price$12.75
Upside/Downside68.43%
GradeFair
TypeGrowth
Risk Assessment
Beta1.58
Volatility60.49%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.